Published in Healthcare Finance, Tax and Law Weekly, June 14th, 2006
"We are honored to be selected for inclusion in the NASDAQ Biotechnology Index," said Michael J. Valentino, president & CEO. "To join other leading companies in the NASDAQ Biotechnology Index is further recognition of Adams' successful business model and our dedication to building stockholder value. Since our IPO last July, our overall business has experienced tremendous growth, producing excellent results in both net sales and profits."
Launched in 1993, the NASDAQ Biotechnology Index includes securities of NASDAQ listed companies...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.